Loading
Distinct shells carrying a filed role for this person — not every shell they have ever touched.
Of those vehicles, the ones that closed a merger.
Announced but not closed, and still hunting.
No closed vehicle here has both a stored price and a filed trust value to score it against.
1 vehicle on file, newest listing first
none appears on more than one
Michael Cam-Phung is a Boston-based executive, investor, and SPAC sponsor who currently serves as Chairman and Director of Cambridge Acquisition Corp. (NASDAQ: CAQ), a special purpose acquisition company incorporated in 2025 that filed with the SEC in December 2025 to raise up to $200 million in an IPO of 20 million units priced at $10.00 each. As the managing member of Cambridge Acquisition's sponsor, Cam-Phung controls 7,666,667 founder shares and holds a reported 10% ownership stake in the SPAC. Cambridge Acquisition targets category-defining businesses in high-growth markets, with a particular focus on technology-enabled platforms in sectors such as harm-reduction, wellness-oriented products, hemp-derived or functional botanical consumables, psychedelics, and health-oriented markets. BTIG is serving as sole bookrunner on the offering. The company is headquartered at One Liberty Square, 13th Floor, Boston, Massachusetts.
In his operating career, Cam-Phung has served as Chief Strategy Officer at SEISA Medical, a Pennsylvania-based medical device company, since joining in 2019. In that role he has been instrumental in driving the company's growth strategy and M&A activity, completing several key acquisitions including Burpee MedSystems, ProtoQuick, and Peridot Corporation, and ultimately leading an exit to a strategic buyer in 2023. He has also been identified as VP and Head of Medtech Solutions Strategy at Tekni-Plex. Prior to his medical device leadership roles, Cam-Phung spent approximately nine years in private equity and growth equity as a Principal at Highland Consumer Partners, where he focused on consumer goods, services, and specialty retailers and was actively involved in the firm's investments in True Science, City Sports, Pharmaca, Life Gear, and Guitar Center. He began his finance career in BMO's Debt Capital Markets group before transitioning to Consumer & Retail corporate finance coverage as a Senior Analyst at William Blair & Company. Since 2016, he has also served as an advisor to Bail Capital and its predecessor organization, Bailey Capital Management.
Beyond his primary roles, Cam-Phung holds a board seat at Indochino Apparel, Inc. and is an active angel investor with interests in finished medical devices, advanced catheter and assembly manufacturing, and stents. He graduated from the University of Chicago with an A.B. in Economics and Public Policy. His expertise spans business strategy, M&A execution, private equity, growth equity, and venture capital, with a track record that spans consumer, retail, and medical technology sectors. The Cambridge Acquisition team he leads combines private equity, venture capital, operational leadership, and public market experience, with principals who have backed category leaders such as JUUL, Compass Pathways, MindMed, Beckley Psytech, and Mindbloom, several of which achieved public market listings.
This record is keyed to SEC CIK 0002085776 — the identifier this person files under in their own name. Every vehicle above is a filing made under that CIK, so “the same person on two shells” is a fact about an SEC identifier rather than about a name that happens to match.
Roles are the strings the filings used, in the order they were filed. Nothing on this page ranks them, infers seniority, or offers a reason why any two of these names recur — a recurrence is a count, and the filings that produced it are linked beside every row. We also hold 6 institutional-holder rows on these vehicles, under 5 distinct name strings, and none of them is counted across vehicles: that table has no CIK column, and matching holders by name would merge firms that are not the same firm.